Evotec's Abu Dhabi Register Change Is Not a Sell Signal — and Neither Is the Beat a Guidance Upgrade

Two separate disclosures landed on Evotec this week, and both are easy to misread. The first is a voting-rights filing from the Government of Abu Dhabi. The second is a pair of analyst notes reacting to preliminary nine-month figures. Neither one, on close inspection, says what the headlines might suggest.

What the threshold notice actually records

Thursday's mandatory disclosure from the Abu Dhabi government shows attributed voting rights falling from 5.62% to 0.00%, with the threshold crossed on 9 October. The stake was held indirectly through Mubadala Investment Company, which also filed the notice on the government's behalf.

That distinction matters. The filing documents a change in the voting rights attributed to the Abu Dhabi government — it is not a statement that Mubadala has sold every Evotec share it owns. Reading a full economic exit by Mubadala into the reported government figure would go well beyond what the notice says. Investors weighing the news should keep the reported voting-rights percentage separate from any concrete share transaction; the disclosure records a shift at the level of the Abu Dhabi government, nothing more.

The operating picture is a different question entirely

Evotec's preliminary results for the first nine months of 2026 point to group revenue of roughly EUR 465.0 million and an adjusted group EBITDA of about EUR -42.8 million. Both figures came in ahead of market expectations, though the company attributed the gap mainly to the timing of consensus estimates rather than to any underlying acceleration. The beat, in other words, did not come with a raised outlook.

For the full year, Evotec reiterated revenue of around EUR 570 million to EUR 610 million and adjusted EBITDA of roughly EUR -70 million to EUR -105 million. At constant currencies, the confirmed guidance implies revenue of EUR 595 million to EUR 635 million and adjusted EBITDA of around EUR -60 million to EUR -90 million — part of the existing outlook, not a fresh upgrade. Note too that the interim numbers are unaudited, and that an adjusted operating result still deep in negative territory is not a return to profit.

Same numbers, opposite conclusions

RBC Capital Markets reaffirmed "Outperform" with a EUR 10 price target on Wednesday. Deutsche Bank Research stayed at "Hold" and EUR 3.50 a day later. Charles Weston of RBC pointed to revenue and operating profit beating expectations, plus the confirmed annual guidance, and left his positive rating unchanged after the release. Fynn Scherzler of Deutsche Bank likewise acknowledged the stronger figures but described the fourth-quarter outlook as surprisingly murky from a market perspective — a more cautious stance that questions not the beat itself but how durable the business trend is beyond the reporting period.

The split is instructive: identical data can support both confidence and restraint, precisely because the full-year plan was left untouched and still carries a loss.

What to watch on 5 November

Evotec will publish the complete third-quarter and nine-month 2026 results on 5 November. That report should allow a closer read on whether the preliminary surprise reflects genuine momentum or simply estimate timing. Until then, two valuation threads run in parallel: the changed attribution of voting rights on one side, and execution against confirmed — and still loss-making — targets on the other. Neither thread, on its own, rewrites the investment case.